HIV-1 drug resistance (HIVDR) genotyping is an essential component of the WHO global HIVDR surveillance strategy. Plasma “gold standard” specimen type for HIVDR genotyping, but its use may not be feasible in rural, remote areas in low- and middle-income countries, since preparing and storing it ...require personnel and laboratory infrastructure that are often lacking. An alternative specimen type is dried blood spots (DBS), which can be made without special laboratory processing. DBS are more easily transported than plasma because they can be shipped at ambient temperature as non-hazardous materials using regular mail or courier services.
3rd edition
more
This document is written for medical doctors, clinical officers, medical assistants, nurses, midwives, health surveillance assistants (HSAs), and medical records clerks who are working in public and private sector health facilities in Malawi. It is designed to be a practical guide for implementation... of integrated HIV services.
more
National estimates have been developed every two years since 2003, led by the NCASC with close collaboration from a range of technical experts, partners and epidemiologists from the UNAIDS, WHO and FHI. This contains information about estimations of adult HIV prevalence.
Downloaded free from http://www.j-hhr.org on Monday, March 06, 20
Journal of HIV and Human Reproduction: Year : 2015, volume : 3, Issue : 2, Page : 47-55
Risk of spill-over of EVD to Uganda has been categorised as very high. On 28 September 2018, WHO elevated the risk at the regional level which includes Uganda from ‘high’ to ‘very high’. Uganda has a very long and largely porous border with the DRC. High population movements across the borde...rs occur for various reason including for trade, social activities and services and asylum. There are cross-border markets in several border districts in Uganda and DRC that involve thousands of people crossing into and out of DRC and Uganda for trade purposes several days in a week.
more
This fourth progress report November 2020 of the Global HIV Prevention Coalition reviews the progress in the 28 focus countries and complements the three previous progress reports. This report describes key developments in 2019–2020, identifies challenges and opportunities (including those associa...ted with the COVID-19 pandemic) and outlines priorities for the years ahead. It is divided into two main sections.
more